Breaking News
A recent study of Moderna’s combination influenze (flu) and COVID-18 vaccine, mRNA-1083, found that it induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all four influenza strains (among those ages 50 to 64 years), the three clinically relevant influenza strains (among those aged 65 years and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.
Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis
BioTrending
- By Trudie Mitschang
When it comes to online health information, the Internet is a place where falsehoods flourish. Combating questionable content is no easy task, requiring education, legislation and diligence from stakeholders in the healthcare, scientific and public health communities.
- By Meredith Whitmore
Your words, tone and body language can escalate patient fears, but they also have the power to ease anxiety and help patients cope.
- By Jim Trageser
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
- By Keith Berman, MPH, MBA
With 16 FVIII products now approved for the treatment of hemophilia A, many patients with this disease are now able to live a normal life.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
